---
schema_version: "secwatch.filing_event.v1"
accession: "0001601830-26-000080"
form_type: "8-K"
ticker: "RXRX"
cik: "0001601830"
company_name: "RECURSION PHARMACEUTICALS, INC."
filed_at: "2026-06-18T21:04:30+00:00"
generated_at: "2026-06-18T21:10:26.716625+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Recursion Pharma 2026 annual meeting elects directors, approves exec compensation, ratifies auditor

## Summary
- Elected Najat Khan, Ph.D. and Franziska Michor, Ph.D. as Class II directors until 2029 annual meeting.
- Advisory vote on executive compensation passed: 206,171,008 for, 30,893,147 against, 1,280,852 abstain.
- Ratified PricewaterhouseCoopers LLP as independent auditor for FY2026: 361,743,500 for, 2,148,771 against, 1,128,498 abstain.
- Broker non-votes of 126,675,762 on director and compensation proposals.

## SEC filing metadata
- accession: 0001601830-26-000080
- form_type: 8-K
- ticker: RXRX
- cik: 0001601830
- company_name: RECURSION PHARMACEUTICALS, INC.
- filed_at: 2026-06-18T21:04:30+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1601830/000160183026000080/0001601830-26-000080-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1601830/000160183026000080/rxrx-20260617.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001601830-26-000080
- JSON: https://secwatch.observer/filing/0001601830-26-000080.json
- Plain text: https://secwatch.observer/filing/0001601830-26-000080.txt

## Key facts
- Shareholder Votes
  RECURSION PHARMACEUTICALS, INC. shareholders approved Election of Class II directors at the 2026-06-17 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2026-06-17
  source text: Proposal 1: The stockholders elected as Class II directors the two individuals listed below to serve until the Company’s 2029 annual meeting of stockholders, or until their respective successors are duly elected and qualified. The voting results were as follows: Nominee For Withheld Broker Non-Votes Najat Khan, Ph.D. 210,437,751 27,907,256 126,675,762 Franziska Michor, Ph.D. 208,124,737 30,220,270 126,675,762
  evidence_url: https://www.sec.gov/Archives/edgar/data/1601830/000160183026000080/0001601830-26-000080-index.htm
- Shareholder Votes
  RECURSION PHARMACEUTICALS, INC. shareholders approved Advisory vote to approve executive compensation at the 2026-06-17 meeting.
  - Proposal: say on pay
  - Outcome: passed
  - Meeting: 2026-06-17
  source text: Proposal 2: The advisory resolution to approve executive compensation, as disclosed in the Proxy Statement, was approved, with the following votes cast: For Against Abstain Broker Non-Votes 206,171,008 30,893,147 1,280,852 126,675,762
  evidence_url: https://www.sec.gov/Archives/edgar/data/1601830/000160183026000080/0001601830-26-000080-index.htm
- Shareholder Votes
  RECURSION PHARMACEUTICALS, INC. shareholders approved Ratification of appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm at the 2026-06-17 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2026-06-17
  source text: Proposal 3: The appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for the year ending December 31, 2026 was ratified, with the following votes cast: For Against Abstain 361,743,500 2,148,771 1,128,498
  evidence_url: https://www.sec.gov/Archives/edgar/data/1601830/000160183026000080/0001601830-26-000080-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.